Rahib, L., Wehner, M. R., Matrisian, L. M. & Nead, K. T. Estimated projection of US cancer incidence and death to 2040. JAMA Netw. Open 4, e214708 (2021).
Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023).
Encarnacion-Rosado, J. & Kimmelman, A. C. Harnessing metabolic dependencies in pancreatic cancers. Nat. Rev. Gastroenterol. Hepatol. 18, 482–492 (2021).
Martinez-Reyes, I. & Chandel, N. S. Cancer metabolism: looking forward. Nat. Rev. Cancer 21, 669–680 (2021).
Ginguay, A., Cynober, L., Curis, E. & Nicolis, I. Ornithine aminotransferase, an important glutamate-metabolizing enzyme at the crossroads of multiple metabolic pathways. Biology (Basel) 6, 18 (2017).
Casero, R. A. Jr, Murray Stewart, T. & Pegg, A. E. Polyamine metabolism and cancer: treatments, challenges and opportunities. Nat. Rev. Cancer 18, 681–695 (2018).
Zaytouni, T. et al. Critical role for arginase 2 in obesity-associated pancreatic cancer. Nat. Commun. 8, 242 (2017).
Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656–670 (2012).
Son, J. et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101–105 (2013).
Vande Voorde, J. et al. Improving the metabolic fidelity of cancer models with a physiological cell culture medium. Sci. Adv. 5, eaau7314 (2019).
Hensley, C. T. et al. Metabolic heterogeneity in human lung tumors. Cell 164, 681–694 (2016).
Sullivan, M. R. et al. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. eLife 8, e44235 (2019).
Tsai, P. Y. et al. Adaptation of pancreatic cancer cells to nutrient deprivation is reversible and requires glutamine synthetase stabilization by mTORC1. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.2003014118 (2021).
Apiz-Saab, J. J. et al. Pancreatic tumors activate arginine biosynthesis to adapt to myeloid-driven amino acid stress. Preprint at bioRxiv https://doi.org/10.1101/2022.06.21.497008 (2022).
Menjivar, R. E. et al. Arginase 1 is a key driver of immune suppression in pancreatic cancer. eLife 12, e80721 (2023).
Miska, J. et al. Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma. Sci. Adv. 7, eabc8929 (2021).
Gitto, S. B. et al. Difluoromethylornithine combined with a polyamine transport inhibitor is effective against gemcitabine resistant pancreatic cancer. Mol. Pharm. 15, 369–376 (2018).
Nilsson, J. A. et al. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 7, 433–444 (2005).
Meyskens, F. L. Jr & Gerner, E. W. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin. Cancer Res. 5, 945–951 (1999).
Holbert, C. E., Cullen, M. T., Casero, R. A. Jr & Stewart, T. M. Polyamines in cancer: integrating organismal metabolism and antitumour immunity. Nat. Rev. Cancer 22, 467–480 (2022).
Daune, G., Gerhart, F. & Seiler, N. 5-Fluoromethylornithine, an irreversible and specific inhibitor of l-ornithine:2-oxo-acid aminotransferase. Biochem. J. 253, 481–488 (1988).
Seiler, N., Sarhan, S. & Knodgen, B. Inhibition of ornithine aminotransferase by 5-fluoromethylornithine: protection against acute thioacetamide intoxication by elevated tissue ornithine levels. Pharmacol. Toxicol. 70, 373–380 (1992).
Zielonka, M. et al. Pharmacologic rescue of hyperammonemia-induced toxicity in zebrafish by inhibition of ornithine aminotransferase. PLoS ONE 13, e0203707 (2018).
Burns, M. R., Graminski, G. F., Weeks, R. S., Chen, Y. & O’Brien, T. G. Lipophilic lysine–spermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitor. J. Med. Chem. 52, 1983–1993 (2009).
Samal, K. et al. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport. Int. J. Cancer 133, 1323–1333 (2013).
Puleston, D. J. et al. Polyamine metabolism is a central determinant of helper T cell lineage fidelity. Cell 184, 4186–4202.e20 (2021).
Wagner, A. et al. Metabolic modeling of single Th17 cells reveals regulators of autoimmunity. Cell 184, 4168–4185.e21 (2021).
Alexander, E. T., Minton, A., Peters, M. C., Phanstiel, O. T. & Gilmour, S. K. A novel polyamine blockade therapy activates an anti-tumor immune response. Oncotarget 8, 84140–84152 (2017).
Hayes, C. S. et al. Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment. Cancer Immunol. Res. 2, 274–285 (2014).
Park, M. H., Nishimura, K., Zanelli, C. F. & Valentini, S. R. Functional significance of eIF5A and its hypusine modification in eukaryotes. Amino Acids 38, 491–500 (2010).
Hardbower, D. M. et al. Ornithine decarboxylase regulates M1 macrophage activation and mucosal inflammation via histone modifications. Proc. Natl Acad. Sci. USA 114, E751–E760 (2017).
Pasini, A., Caldarera, C. M. & Giordano, E. Chromatin remodeling by polyamines and polyamine analogs. Amino Acids 46, 595–603 (2014).
Perera, R. M. & Bardeesy, N. Pancreatic cancer metabolism: breaking it down to build it back up. Cancer Discov. 5, 1247–1261 (2015).
Croghan, M. K., Aickin, M. G. & Meyskens, F. L. Dose-related α-difluoromethylornithine ototoxicity. Am. J. Clin. Oncol. 14, 331–335 (1991).
Romijn, J. C., Verkoelen, C. F. & Splinter, T. A. Problems of pharmacokinetic studies on α-difluoromethylornithine in mice. Cancer Chemother. Pharmacol. 19, 30–34 (1987).
Iwami, K., Wang, J. Y., Jain, R., McCormack, S. & Johnson, L. R. Intestinal ornithine decarboxylase: half-life and regulation by putrescine. Am. J. Physiol. 258, G308–G315 (1990).
Kobayashi, K., Morris, H. P. & Katunuma, N. Studies on the turnover rates of ornithine aminotransferase in Morris hepatoma 44 and host liver. J. Biochem. 80, 1085–1089 (1976).
Simell, O. & Takki, K. Raised plasma-ornithine and gyrate atrophy of the choroid and retina. Lancet 1, 1031–1033 (1973).
Bolkenius, F. N., Knodgen, B. & Seiler, N. dl-canaline and 5-fluoromethylornithine. Comparison of two inactivators of ornithine aminotransferase. Biochem. J. 268, 409–414 (1990).
Halmekyto, M., Alhonen, L., Alakuijala, L. & Janne, J. Transgenic mice over-producing putrescine in their tissues do not convert the diamine into higher polyamines. Biochem. J. 291, 505–508 (1993).
Zigmond, E. et al. Suppression of hepatocellular carcinoma by inhibition of overexpressed ornithine aminotransferase. ACS Med. Chem. Lett. 6, 840–844 (2015).
Mendoza, M. C., Er, E. E. & Blenis, J. The Ras–ERK and PI3K–mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36, 320–328 (2011).
Bodoky, G. et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest. New Drugs 30, 1216–1223 (2012).
Kenney, C. et al. Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. Invest. New Drugs 39, 821–828 (2021).
Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437–450 (2003).
Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418–425 (2001).
Sastra, S. A. & Olive, K. P. Quantification of murine pancreatic tumors by high-resolution ultrasound. Methods Mol. Biol. 980, 249–266 (2013).
Wapnir, I. L., Wartenberg, D. E. & Greco, R. S. Three dimensional staging of breast cancer. Breast Cancer Res. Treat. 41, 15–19 (1996).
Samuels, Y. et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561–573 (2005).
Debnath, J., Muthuswamy, S. K. & Brugge, J. S. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30, 256–268 (2003).
Siddiqui, K. M. & Chopra, D. P. Primary and long term epithelial cell cultures from human fetal normal colonic mucosa. In Vitro 20, 859–868 (1984).
Marin-Valencia, I. et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 15, 827–837 (2012).
Mascanfroni, I. D. et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α. Nat. Med. 21, 638–646 (2015).
Chong, J., Wishart, D. S. & Xia, J. Using MetaboAnalyst 4.0 for comprehensive and integrative metabolomics data analysis. Curr. Protoc. Bioinformatics 68, e86 (2019).
Bookout, A. L. & Mangelsdorf, D. J. Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways. Nucl. Recept. Signal. 1, e012 (2003).
Tang, Z. et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98–W102 (2017).
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
The R Development Core Team. R: A language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2016).
Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).
Feng, J., Liu, T., Qin, B., Zhang, Y. & Liu, X. S. Identifying ChIP-seq enrichment using MACS. Nat. Protoc. 7, 1728–1740 (2012).
Consortium, E. P. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).
Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010).
Ramirez, F., Dundar, F., Diehl, S., Gruning, B. A. & Manke, T. deepTools: a flexible platform for exploring deep-sequencing data. Nucleic Acids Res. 42, W187–191 (2014).
Roehle, K. et al. cIAP1/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes. Sci. Transl Med. 13, eabf5058 (2021).
More News
A deconstruction-reconstruction strategy for pyrimidine diversification – Nature
‘Orangutan, heal thyself’: First wild animal seen using medicinal plant
UTIs make life miserable — scientists are finding new ways to tackle them